Skip to main content
. Author manuscript; available in PMC: 2019 Oct 4.
Published in final edited form as: Mol Cell. 2018 Sep 20;72(1):60–70.e3. doi: 10.1016/j.molcel.2018.08.025

Fig 4 : Re-balancing of abundance of anti and pro-apoptotic Bcl family proteins:

Fig 4 :

(A,B) Anti- and proapoptotic signaling was measured in WT and LOI cells by immunoblotting for Bax and Bcl-2 proteins. Blots are shown for biological triplicates; (C) Anti and pro-apoptotic transcript levels of Bcl-2 and Bcl-Xl along with Bax and Bak-1 were measured in LOI and WT cells; (D,E) Effect of Erk inhibition on Bax and Bcl-2 levels was measured in LOI cells treated with increasing dose of the Mek1,2 inhibitor U0126 in 3 biological replicates; (F) Joint distribution of Bax and Bcl-2 in the same individual WT and LOI cells were measured by immunofluorescence staining. The marginal distributions, the sample mean and variance for the distributions were estimated (shown at the bottom); (G) The computational model of IGF2 signaling was extended to include Bax, Bcl-2 levels as proportional to the time integrals of the Akt, Erk signaling. H) The predicted Akt, Erk signaling of the computational model was integrated over time to obtain estimates of Bax and Bcl-2 levels.